SLC5A2 and type 2 diabetes mellitus: It is also notable that in a meta-analysis of 18 randomised controlled trials, T2DM individuals taking SGLT2 inhibitors (to reduce renal glucose absorption) had significantly higher serum magnesium compared to those taking the placebo.